$DYN
Dyne Therapeutics Inc

2022 Q2 Form 10-Q Financial Statement

#000095017022006860 Filed on May 02, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.091M $7.547M $6.510M
YoY Change -3.21% 15.93%
% of Gross Profit
Research & Development $46.66M $28.24M $18.63M
YoY Change 95.48% 51.6% 205.88%
% of Gross Profit
Depreciation & Amortization $500.0K $400.0K $200.0K
YoY Change 150.0% 100.0% 33.33%
% of Gross Profit
Operating Expenses $52.76M $35.78M $25.13M
YoY Change 74.89% 42.37% 220.06%
Operating Profit -$52.76M -$35.78M -$25.13M
YoY Change 74.89% 42.37% 220.06%
Interest Expense $441.0K $230.0K $170.0K
YoY Change 110.0% 35.29%
% of Operating Profit
Other Income/Expense, Net $451.0K $200.0K $166.0K
YoY Change 114.76% 20.48% -603.03%
Pretax Income -$52.30M -$35.58M -$24.97M
YoY Change 74.61% 42.5%
Income Tax
% Of Pretax Income
Net Earnings -$52.30M -$35.58M -$24.97M
YoY Change 74.61% 42.51% 216.61%
Net Earnings / Revenue
Basic Earnings Per Share -$1.01 -$0.69
Diluted Earnings Per Share -$1.01 -$689.6K -$504.8K
COMMON SHARES
Basic Shares Outstanding 51.65M 51.64M
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $291.8M $323.2M $483.1M
YoY Change -33.0% -33.11%
Cash & Equivalents $136.0M $148.0M $310.9M
Short-Term Investments $155.9M $175.2M $172.1M
Other Short-Term Assets $6.096M $21.30M $4.000M
YoY Change -76.29% 432.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $297.9M $344.5M $487.1M
YoY Change -35.41% -29.28%
LONG-TERM ASSETS
Property, Plant & Equipment $5.483M $5.619M $1.777M
YoY Change 111.78% 216.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.315M $2.313M $2.300M
YoY Change -19.76% 0.57%
Total Long-Term Assets $42.09M $43.31M $4.642M
YoY Change 619.52% 833.05%
TOTAL ASSETS
Total Short-Term Assets $297.9M $344.5M $487.1M
Total Long-Term Assets $42.09M $43.31M $4.642M
Total Assets $340.0M $387.8M $491.7M
YoY Change -27.21% -21.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.972M $5.188M $5.760M
YoY Change 23.42% -9.93%
Accrued Expenses $18.65M $18.05M $7.700M
YoY Change 109.5% 134.4%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $25.62M $23.24M $13.50M
YoY Change 76.08% 72.13%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $27.35M $28.07M
YoY Change
Total Long-Term Liabilities $27.35M $28.07M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $25.62M $23.24M $13.50M
Total Long-Term Liabilities $27.35M $28.07M $0.00
Total Liabilities $52.97M $51.30M $13.45M
YoY Change 264.01% 281.43%
SHAREHOLDERS EQUITY
Retained Earnings -$316.4M -$264.1M -$104.2M
YoY Change 153.53%
Common Stock $6.000K $6.000K $6.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $287.1M $336.5M $478.3M
YoY Change
Total Liabilities & Shareholders Equity $340.0M $387.8M $491.7M
YoY Change -27.21% -21.14%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$52.30M -$35.58M -$24.97M
YoY Change 74.61% 42.51% 216.61%
Depreciation, Depletion And Amortization $500.0K $400.0K $200.0K
YoY Change 150.0% 100.0% 33.33%
Cash From Operating Activities -$30.91M -$50.74M -$18.39M
YoY Change -33.03% 175.86% 152.37%
INVESTING ACTIVITIES
Capital Expenditures -$261.0K $1.401M $9.000K
YoY Change -64.59% 15466.67% -95.73%
Acquisitions
YoY Change
Other Investing Activities $18.70M -$735.0K -$128.4M
YoY Change -428.6% -99.43%
Cash From Investing Activities $18.44M -$2.136M -$128.4M
YoY Change -386.87% -98.34% 60741.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 99.00K 18.00K 157.3M
YoY Change 296.0% -99.99% 1220.54%
NET CHANGE
Cash From Operating Activities -30.91M -50.74M -18.39M
Cash From Investing Activities 18.44M -2.136M -128.4M
Cash From Financing Activities 99.00K 18.00K 157.3M
Net Change In Cash -12.37M -52.86M 10.48M
YoY Change -76.47% -604.26% 137.74%
FREE CASH FLOW
Cash From Operating Activities -$30.91M -$50.74M -$18.39M
Capital Expenditures -$261.0K $1.401M $9.000K
Free Cash Flow -$30.65M -$52.14M -$18.40M
YoY Change -32.52% 183.34% 145.39%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001818794
CY2021Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
CY2021Q1 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dyn Proceeds From Issuance Follow On Public Offering
ProceedsFromIssuanceFollowOnPublicOffering
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-39509
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Dyne Therapeutics, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
36-4883909
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1560 Trapelo Road
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
CY2022Q1 dei City Area Code
CityAreaCode
781
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
786-8230
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2022Q1 dei Trading Symbol
TradingSymbol
DYN
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
51653523
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
147965000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
200825000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
175185000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
175746000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
21300000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5821000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
344450000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
382392000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5619000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4678000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
35380000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
36282000
CY2022Q1 dyn Restricted Cash And Other Assets Noncurrent
RestrictedCashAndOtherAssetsNoncurrent
2313000
CY2021Q4 dyn Restricted Cash And Other Assets Noncurrent
RestrictedCashAndOtherAssetsNoncurrent
2311000
CY2022Q1 us-gaap Assets
Assets
387762000
CY2021Q4 us-gaap Assets
Assets
425663000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5188000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4031000
CY2022Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13338000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
20799000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4711000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3893000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
23237000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
28723000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28066000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28743000
CY2022Q1 us-gaap Liabilities
Liabilities
51303000
CY2021Q4 us-gaap Liabilities
Liabilities
57466000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
51667060
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
51607522
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51649423
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51569381
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
6000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
601440000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
596934000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-930000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-269000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-264057000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-228474000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
336459000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
368197000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
387762000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
425663000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28236000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18625000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7547000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6509000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
35783000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
25134000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-35783000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-25134000
CY2022Q1 us-gaap Interest Income Other
InterestIncomeOther
230000
CY2021Q1 us-gaap Interest Income Other
InterestIncomeOther
166000
CY2022Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
30000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
200000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
166000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-35583000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-24968000
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.50
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
51601444
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49472497
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-35583000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-24968000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-661000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-41000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36244000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25009000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
368197000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
18000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
342367000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4488000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-661000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-35583000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
336459000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
157237000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3652000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-41000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-24968000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
478260000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-35583000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-24968000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4488000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3652000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
425000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
238000
CY2022Q1 dyn Non Cash Lease Expense
NonCashLeaseExpense
1041000
CY2021Q1 dyn Non Cash Lease Expense
NonCashLeaseExpense
-7000
CY2022Q1 dyn Amortization Accretion Of Premium Discount On Marketable Securities
AmortizationAccretionOfPremiumDiscountOnMarketableSecurities
605000
CY2021Q1 dyn Amortization Accretion Of Premium Discount On Marketable Securities
AmortizationAccretionOfPremiumDiscountOnMarketableSecurities
492000
CY2022Q1 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
30000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
15477000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-331000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
-6268000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
1869000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50739000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18393000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1401000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9000
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
55327000
CY2021Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
132186000
CY2022Q1 dyn Maturities Of Marketable Securities
MaturitiesOfMarketableSecurities
52077000
CY2021Q1 dyn Maturities Of Marketable Securities
MaturitiesOfMarketableSecurities
3820000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2515000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2136000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-128375000
CY2021Q1 dyn Proceeds From Issuance Follow On Public Offering
ProceedsFromIssuanceFollowOnPublicOffering
157237000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
18000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
157250000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-52857000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10482000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
203519000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
303153000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
150662000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
313635000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
167000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
59000
CY2022Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2017-12-01
CY2022Q1 us-gaap Dividends Common Stock
DividendsCommonStock
8992216000
CY2021Q1 us-gaap Dividends Common Stock
DividendsCommonStock
7560471000
CY2022Q1 dyn Cash And Cash Equivalents Maturity Period
CashAndCashEquivalentsMaturityPeriod
P90D
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
2700000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
2700000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
147965000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
200825000
CY2022Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
384000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
383000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2313000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2311000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
150662000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
203519000
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
176115000
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
934000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
175185000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
176015000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
272000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
175746000
CY2022Q1 dyn Fair Value Assets Transfers Amount
FairValueAssetsTransfersAmount
0
CY2021Q4 dyn Fair Value Assets Transfers Amount
FairValueAssetsTransfersAmount
0
CY2022Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
150149000
CY2022Q1 dyn Available For Sale Debt Securities Maturing In One Year Through Two Years
AvailableForSaleDebtSecuritiesMaturingInOneYearThroughTwoYears
25036000
CY2022Q1 dyn Available For Sale Debt Securities Maturity After Year Two Years Fair Value
AvailableForSaleDebtSecuritiesMaturityAfterYearTwoYearsFairValue
0
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
175185000
CY2022Q1 dyn Accrued Facility Costs Current
AccruedFacilityCostsCurrent
0
CY2021Q4 dyn Accrued Facility Costs Current
AccruedFacilityCostsCurrent
62000
CY2022Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13338000
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8027000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6661000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2408000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1983000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5619000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4678000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
400000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
200000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1398000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5097000
CY2022Q1 dyn Accrued Consulting Services Current
AccruedConsultingServicesCurrent
412000
CY2021Q4 dyn Accrued Consulting Services Current
AccruedConsultingServicesCurrent
694000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
455000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
184000
CY2022Q1 dyn Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
11073000
CY2021Q4 dyn Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
14762000
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
11253000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
7948671
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
9.30
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y6M
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
26071000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
400000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
20799000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.73
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.74
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0147
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0244
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0088
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0113
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7967750
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.35
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M12D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
36946000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
173293
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.85
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
9583
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.93
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
182789
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.12
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7948671
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.30
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
26071000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2301146
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.67
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y1M6D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.75
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.44
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4488000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3652000

Files In Submission

Name View Source Status
0000950170-22-006860-index-headers.html Edgar Link pending
0000950170-22-006860-index.html Edgar Link pending
0000950170-22-006860.txt Edgar Link pending
0000950170-22-006860-xbrl.zip Edgar Link pending
dyn-20220331.htm Edgar Link pending
dyn-20220331.xsd Edgar Link pending
dyn-20220331_cal.xml Edgar Link unprocessable
dyn-20220331_def.xml Edgar Link unprocessable
dyn-20220331_htm.xml Edgar Link completed
dyn-20220331_lab.xml Edgar Link unprocessable
dyn-20220331_pre.xml Edgar Link unprocessable
dyn-ex31_1.htm Edgar Link pending
dyn-ex31_2.htm Edgar Link pending
dyn-ex32_1.htm Edgar Link pending
dyn-ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending